Experimental study evaluates tapinarof combined with narrowband ultraviolet B phototherapy for psoriasis, suggesting potential synergistic therapeutic efficacy.
Key Points
Investigate the therapeutic potential of combining the aryl hydrocarbon receptor agonist tapinarof with narrowband ultraviolet B phototherapy for managing psoriasis.
Evaluated combinational treatment combining topical application of the aryl hydrocarbon receptor agonist tapinarof with narrowband ultraviolet B light exposure.
Specific cohort size, blinding methods, and trial design specifics were not detailed in the provided abstract.
Primary endpoint data, event rates, effect sizes, and significance values were omitted from the provided text.
Investigation focuses qualitatively on combining receptor-targeted topical treatment with light therapy for synergistic anti-psoriatic disease control.